U.S. marijuana companies completed fewer capital raises in 2024 than in the year prior, but raised a good bit more money overall with the funding that did materialize, suggesting that some investors may be warming back up to the cannabis space. That’s the macro takeaway from Viridian Capital Advisors’ latest …
DEA Judge Stays Marijuana Scheduling Proceedings
The judges’s decision cancels the previously scheduled hearing, set to begin next week, during which time proponents and opponents of marijuana rescheduling were to testify and face cross-examination. The post DEA Judge Stays Marijuana Scheduling Proceedings appeared first on NORML.
DEA judge cancels upcoming cannabis rescheduling hearings
The cannabis rescheduling saga hit a new snag, with a chance the policy change could be nixed altogether. A Drug Enforcement Administration judge on Monday canceled marijuana rescheduling hearings set to begin next week and put the process on hold for at least three months, giving pro-rescheduling groups time to …
U.S. legalization could add $250 million to Tilray’s books
Despite delays in cannabis legalization efforts in the U.S., Tilray (NASDAQ: TLRY) still has its eyes on that prize. The company’s CEO, Irwin Simon, told investors on the company’s earnings call that if the U.S. legalized medical marijuana, it would “represent an additional $250-million opportunity for Tilray.” He based that figure …